Safety Profile Of Bortezomib Impacts Survival Of Cardiac AL Amyloidosis
Zoé Van de Wyngaert(Centre Hospitalier Universitaire de Lille), Xavier Leleu(Inserm), Hélène Demarquette(Ikerbasque), É. Hachulla(Centre Hospitalier Universitaire de Lille), Nicolas Lamblin(Inserm), Sarah Bonnet(Hôpital Saint Eloi), Guillemette Fouquet(Centre Hospitalier Universitaire de Lille), David Launay(Inserm), Greg Vanoutryve(Hôpital Claude Huriez), Charles Herbaux(Centre Hospitalier Universitaire de Lille), Mathieu Wémeau(Inserm), Stéphanie Guidez(Inserm), Louis Terriou(Centre Hospitalier Universitaire de Lille), David Beauvais(Hôpital Claude Huriez), Bénédicte Hivert(Hôpital Saint-Vincent-de-Paul)
Cited by 0
Related Papers
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
|New England Journal of Medicine|2009|857
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Mapping and predicting mortality from systemic sclerosis
|Annals of the Rheumatic Diseases|2017|699